LRRK2 and Parkinson disease: A scalable and sensitive mass-spectrometry-based proteomics workflow has also been developed to examine cerebrospinal fluid proteome profiling, revealing changes in proteins for Parkinson’s disease patients and enhanced neuroinflammation signatures in individuals with LRRK2 G2019S mutations, the most common genetic cause of autosomal dominant Parkinson’s disease.